U.S. FDA sends drug advertising warning letters to Lilly, Novo, Hims

The U.S. Food and Drug Administration issued warning letters to Eli Lilly, Novo Nordisk and telehealth firm Hims & Hers Health last week as part of President Donald Trump's order to crack down on drug ... Read More

Hims & Hers shares drop 6% after FDA warning on semaglutide marketing claims

Hims & Hers Health Inc. (NYSE: HIMS) saw its stock fall 6% on Tuesday following the release of a warning letter from the US Food and Drug Administration (FDA) concerning marketing claims related to ... Read More

FDA Cracks Down on Hims, Other Telehealth Companies Over Drug Ads

On Tuesday, the U.S. Food and Drug Administration (FDA) released more than 100 warning letters aimed at both drugmakers and online health companies. Among them: Hims & Hers, a telehealth platform that ... Read More

Fact Check: Ozempic, other weight-loss drug makers face lawsuits. Here's what we know

Pharmaceutical companies behind weight loss and diabetes medication such as Ozempic are facing a lawsuit that could potentially pay out more than $2 billion. There is multidistrict litigation, or an ... Read More

Europe warns consumers about 'sharp rise' in counterfeit versions of Novo, Lilly weight loss drugs

In April, the FDA sounded a familiar warning to consumers of an ongoing problem in the U.S.—the sale of unauthorized compounded and counterfeit versions of Novo Nordisk’s and Eli Lilly’s popular ... Read More